Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Other Non-Current Assets: 2019-2024

  • Pharming Group N.V's Other Non-Current Assets fell 1.51% to $1.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.5 million, marking a year-over-year decrease of 1.51%. This contributed to the annual value of $1.5 million for FY2024, which is 1.51% down from last year.
  • Per Pharming Group N.V's latest filing, its Other Non-Current Assets stood at $1.5 million for Q4 2024, which was down 1.51% from $1.5 million recorded in Q4 2023.
  • Over the past 5 years, Pharming Group N.V's Other Non-Current Assets peaked at $1.5 million during Q4 2023, and registered a low of $1.0 million during Q4 2021.
  • Over the past 3 years, Pharming Group N.V's median Other Non-Current Assets value was $1.5 million (recorded in 2024), while the average stood at $1.4 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first tumbled by 41.01% in 2020, then soared by 31.20% in 2022.
  • Over the past 5 years, Pharming Group N.V's Other Non-Current Assets (Quarterly) stood at $1.5 million in 2020, then slumped by 33.33% to $1.0 million in 2021, then skyrocketed by 31.20% to $1.3 million in 2022, then climbed by 16.46% to $1.5 million in 2023, then fell by 1.51% to $1.5 million in 2024.
  • Its Other Non-Current Assets was $1.5 million in Q4 2024, compared to $1.5 million in Q4 2023 and $1.3 million in Q4 2022.